Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 6/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18494342 | 0.86 | MAPT (0.41) | ADAM17ALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL22211307 | 0.86 | ADAM17 (0.42) | ADAM17TACR1TACR3SMN1; SMN2 | |
| SCHEMBL4807305 | 0.86 | KDM4E (0.51) | ADAM17ALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL6060766 | 0.84 | HPGD (0.38) | ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL4817042 | 0.83 | ADAM17 (0.45) | ADAM17TACR1TACR3ALDH1A1MAPT | |
| SCHEMBL4817586 | 0.81 | ADAM17 (0.43) | ADAM17TACR1TACR3ALDH1A1ALOX15 | |
| SCHEMBL7442631 | 0.77 | ADAM17 (0.52) | ADAM17TACR1TACR3ALDH1A1MAPT | |
| SCHEMBL7442637 | 0.77 | ADAM17 (0.52) | ADAM17TACR1TACR3ALDH1A1MAPT | |
| SCHEMBL4813131 | 0.77 | BCHE (0.43) | ADAM17TACR1TACR3ALDH1A1MAPT | |
| SCHEMBL4808773 | 0.77 | ADAM17 (0.41) | ADAM17TACR1TACR3ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388103-B2 | Cyclopentane carboxylate compounds, process and intermediates for preparing the same and use thereof | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2008-06-17 | — | — | US | disclosed |
| US-20060094843-A1 | Cyclopentane carboxylate compounds, process and intermediates for preparing the same and use thereof | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2006-05-04 | — | — | US | disclosed |
| WO-2006045246-A1 | CYCLOPENTANE CARBOXYLATE COMPOUNDS, PROCESS AND INTERMEDIATES FOR PREPARING THE SAME AND USE THEREOF | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094843-A1 | Cyclopentane carboxylate compounds, process and intermediates for preparing the same and use thereof | C5, C1S, AKR1C3 | ADAM17 2714/4885TACR1 1258/4885TACR3 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.